Bassuony, N., Zaghloul, W., Abou Elela, M., Elbadrawy, M., Moemen, D. (2023). Line Probe Assay for Rapid Diagnosis of Multidrug Resistant Pulmonary Tuberculosis. test, 32(2), 1-7. doi: 10.21608/ejmm.2023.279737
Nancy Abdulmonem Bassuony; Wafaa Saad Zaghloul; Mohammad Ahmad Abou Elela; Mohamed Khairy Elbadrawy; Dalia Moemen. "Line Probe Assay for Rapid Diagnosis of Multidrug Resistant Pulmonary Tuberculosis". test, 32, 2, 2023, 1-7. doi: 10.21608/ejmm.2023.279737
Bassuony, N., Zaghloul, W., Abou Elela, M., Elbadrawy, M., Moemen, D. (2023). 'Line Probe Assay for Rapid Diagnosis of Multidrug Resistant Pulmonary Tuberculosis', test, 32(2), pp. 1-7. doi: 10.21608/ejmm.2023.279737
Bassuony, N., Zaghloul, W., Abou Elela, M., Elbadrawy, M., Moemen, D. Line Probe Assay for Rapid Diagnosis of Multidrug Resistant Pulmonary Tuberculosis. test, 2023; 32(2): 1-7. doi: 10.21608/ejmm.2023.279737

Line Probe Assay for Rapid Diagnosis of Multidrug Resistant Pulmonary Tuberculosis

Egyptian Journal of Medical Microbiology
Volume 32, Issue 2, April 2023, Pages 1-7    PDF (288.85 K)
Document Type: Review articles
DOI: 10.21608/ejmm.2023.279737
Authors
Nancy Abdulmonem Bassuony* 1; Wafaa Saad Zaghloul1; Mohammad Ahmad Abou Elela1; Mohamed Khairy Elbadrawy2; Dalia Moemen1
1Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
2Chest Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
Abstract
Multidrug-resistant tuberculosis (MDR-TB) is a serious public health problem with ultimate concern in the developing countries, including Egypt. In the global TB report issued in 2021 by World Health Organization (WHO), infection caused by the tubercle bacilli Mycobacterium tuberculosis (MTB) represents the 13th chief cause of mortality worldwide. Effective MDR-TB control counts on the accuracy and rapidity of its diagnosis in order to start the proper treatment regimen and as a result limit the transmission of the resistant isolate. Line probe assay (LPA) and GeneXpert MTB/RIF are two WHO approved probe based molecular assays for rapid detection resistant MTB isolates via screening its nucleic acid for any mutations. For the purpose of finding mutations linked to rifampicin resistance using DNA probes, both techniques focus on the same 81 bp Rifampicin Resistance Determining Region. Line probe assay can detect both rifampicin and isoniazid resistance, thus can detect isoniazid mono resistant isolates, which requires special management protocol, in addition to detecting MDR-TB isolates as well with high sensitivity and specificity.
Keywords
Multidrug-resistant tuberculosis (MDR-TB); Line probe assay (LPA); GeneXpert MTB/RIF (Xpert)
Statistics
Article View: 339
PDF Download: 414